Pfizer’s COVID-19 vaccine is 100% effective in adolescents aged 12 to 15, according to results from a new trial. The company plans to submit the results to the Food and Drug Administration for emergency use authorization as soon as possible. (NPR)

COVID-19 was the third leading cause of death in the U.S. in 2020, ranking behind only heart disease and cancer, according to a new report from the Centers for Disease Control and Prevention. The CDC cited COVID-19 as the underlying cause for more than 340,000 deaths as of this week. (CNBC Weekly)

Former Merck executive Michael Nally will become a partner at life sciences platform firm Flagship Pioneering and serve as chief executive of its startup company Generate Biomedicines. Nally spent 18 years at Merck and had been mentioned as a candidate for the  CEO role, but left the company after Robert Davis was chosen to succeed Ken Frazier. (The Wall Street Journal)

Entrada Therapeutics has attracted $116 million in Series B funding, with the goal of focusing on its first Duchenne muscular dystrophy program. The company plans to expand into other neuromuscular diseases. (Endpoints News)

Delcath Systems says its liver-tumor treatment device Hepzato proved successful in a clinical trial. While the company plans to submit the results to the Food and Drug Administration, questions about the data remain. (STAT)